Form 4: Axsome Director Sells Shares Under 10b5-1 Plan

Axsome Therapeutics Director Roger Jeffs sold 13,464 shares of common stock for a weighted average price of $123.68 per share, completing a pre-approved 10b5-1 plan.

Summary

• Roger Jeffs, a Director of Axsome Therapeutics, Inc. (AXSM), reported a sale of common stock.
• The transaction involved the disposition of 13,464 shares of common stock.
• The shares were sold at a weighted average price of $123.68 per share.
• Individual sale prices ranged from $121.30 to $124.60.
• The sale was executed on September 2, 2025.
• This transaction was conducted pursuant to a pre-approved Rule 10b5-1 trading plan, which has now been completed.
• Following this transaction, Roger Jeffs directly beneficially owns 57,510 shares of common stock.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the sale was pre-planned under a 10b5-1 plan, it still represents a reduction in insider ownership. However, the planned nature mitigates any strong negative interpretation.

Negatives

• A director reduced their direct beneficial ownership in the company by 13,464 shares.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report for a director of a pharmaceutical company. Such transactions are common and typically reflect personal financial planning rather than specific company-related news, especially when conducted under a pre-approved 10b5-1 plan.

Stakeholder Impact

• Shareholders may observe a slight decrease in insider ownership, which is generally viewed as a neutral to slightly negative signal, though mitigated by the pre-planned nature of the sale.

Key Dates

Recommendation

This Form 4 reports a routine insider stock sale by a director under a pre-approved 10b5-1 plan. Such transactions are typically for personal financial management and do not usually signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as this event alone does not provide new information to alter an existing investment thesis.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Common Stock